Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026

Maze Therapeutics will present data on its kidney-disease programs MZE829 and MZE782 at ASN Kidney Week in Denver, October 21–25, 2026. The oral presentation will highlight previously reported Phase 2 HORIZON data for MZE829 in APOL1-mediated kidney disease; two posters will cover preclinical research on SLC6A19 inhibition in chronic kidney disease.

Analysis

The announcement itself looks like a low-information catalyst: previously reported Phase 2 results are unlikely to support a durable re-rating unless the presentation adds clinically meaningful detail on effect size, durability, safety, or patient selection. The October 21–25 meeting may still move MAZE around new disclosures, but the preclinical MZE782 work is validation of a research hypothesis—not evidence of clinical efficacy or near-term revenue. For MZE829, a credible signal could strengthen the APOL1-targeted treatment thesis and raise the competitive bar for Vertex Pharmaceuticals’ inaxaplin program; it would not establish commercial differentiation without comparable efficacy, safety, and dosing data. Over 1–3 months, the key value drivers are whether the data support a credible next-stage trial and whether the company provides a clear development timeline. Over 6–18 months, clinical execution and the funding required to reach meaningful milestones matter more than conference visibility. The bullish case is falsified by weak or non-durable clinical effects, safety concerns, or an unclear path to the next trial. No supplied valuation, cash runway, or option-market data supports a directional or options recommendation.

Key Decisions for Investors

• Do not add MAZE solely on the conference announcement. Treat the meeting as a watch event; compare any new MZE829 detail with the already reported dataset rather than interpreting presentation presence as incremental efficacy evidence.
• Before taking event risk, verify the full HORIZON endpoints, patient count, follow-up, dose response, adverse events, and whether the presentation contains new data. Reassess only if those details materially strengthen the efficacy or safety profile.
• Keep MZE782 on a research watchlist, not in a clinical-value framework: look for a disclosed clinical-development timeline and subsequent human data before assigning meaningful near-term probability to the program.
• For any existing MAZE position, set a post-meeting review trigger around clinical durability, tolerability, and a specific next-trial plan. Weakness on these points would undermine the bullish catalyst thesis; absent new information, there may be no trade.